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Abstract
Bone metastasis, a very common sequelae of cancer, is often associated with great morbidity.
Understanding the biology of bone metastases may lead to therapeutic interventions to target the
metastases. In addition to replacing bone marrow elements, the presence of tumour cells in bone
modulates the normal bone remodelling process. Some tumours result in primarily osteolytic bone
lesions, whereas others are associated with osteoblastic bone lesions. In either case, the resulting
changes in the bone structure result in weakened bone that induces pain and is predisposed to
fracture. The mechanisms through which cancer cells modulate bone remodelling are not clearly
defined, but ongoing research using a variety of animal models will hopefully provide clues to






Bone is the third most common site for metastasis
after lung and liver. Bone metastases are a major
source of morbidity and mortality in patients with
metastatic cancer. Reports on bone metastasis in
veterinary patients are limited, and most of the clin-
ical data and pathophysiologic mechanisms of bone
metastasis are derived from human data or murine
studies. Compared to primary bone tumours, such as
osteosarcoma, that originate in the bone, bonemetas-
tases originate from a distal tumour site that even-
tuallymigrates to bone, although in some instances, a
primary osteosarcoma itself maymetastasize to other
bone sites. In humanbeings, bonemetastases account
for over 99% of all tumours in bone, as opposed to
only 1% for primary bone tumours.
The presence of tumour in the bone affects bone
remodelling. The resultant phenotype depends upon
the tumour type; osteolytic, osteoblastic or both types
of induced changes may occur. For example, whereas
both human breast and prostate carcinomas have a
propensity to metastasize to bone, metastatic breast
cancers usually result in osteolytic lesions and pros-
tate cancer generally produces osteoblastic lesions
(Reddi et al., 2003). In dogs, metastatic tumours
tend to colonize in highly vascularized regions of the
skeleton, including the axial skeleton and proximal
long bones in affected dogs (Durham&Dietze, 1986;
Cooley & Waters, 1998). In humans, the most com-
mon locations of bone metastasis include the spine,
ribs, pelvis, skull and proximal femur (Mirra et al.,
1989). In addition, the most common solid tumours
involved with bone metastasis in humans originate
from prostate, breast, lung, kidney or thyroid gland.
This correlates with metastases in the dog, where
Cooley reported mammary gland, prostate and urin-
ary bladder tumours as the most frequent primary
sites for bone metastasis (Cooley &Waters, 1998).
The metastatic cascade
The metastatic process is complex, and several bar-
riers must be overcome before primary tumour cells
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can spread and multiply at distal sites such as the
bone. This complex pathway is referred to as the
metastatic cascade. Briefly, tumour cells detach from
the primary tumours and invade through their extra-
cellular matrix by utilizing extracellular matrix-
degrading enzymes. In addition, the adhesionproper-
ties of tumour cells may be altered, allowing for their
migration and colonization at novel distal sites.
Tumour cells then intravasate into the bloodstream,
travel within the bloodstream to their target organ
and extravasate into distal sites such as bone. Once at
the target site, the tumour cells successfully reproduce
into a tumour. A variety of growth factors, cytokines
and extracellular–intracellular signalling mechan-
isms, many of which may be unique to their target
site, may be altered to allow bonemetastasis to occur.
Furthermore, angiogenesis plays an important role in
tumour proliferation and survival at distal sites. It is
postulated that the bonemicroenvironment provides
a favourable media for tumours involving the mam-
mary or prostate gland, and communication between
the tumour and stromal tissuemay produce a vicious
cycle ofmetastatic tumour development (Keller et al.,
2001; Cooper et al., 2003). These properties of metas-
tasis need to be investigated, because each stepmay be
a potential target for the development of therapeutic
strategies forminimizing and preventing the spread
of primary tumours to distal sites such as bone.
Properties of bone metastases
There are only limited descriptions of metastasis
to bone in veterinary patients (Cooley & Waters,
1998). Similar to humans, the primary tumours
are typically epithelial in origin (Table 1).
Mesenchymal tumours such as mesothelioma
and aortic body tumours, however, have also
been demonstrated to metastasize to bone. Of
the animal tumours that metastasize to bone,
prostate cancer has received the most attention.
The dog is one of the few animal species that
develops spontaneous prostate cancer and thus
may serve as a valuable model for human disease.
Human prostate cancer is typically considered to
be osteoblastic, i.e. it produces bone. It has been
demonstrated that canine prostate tissue implanted
over the calvaria of mice induces abundant new
woven bone formation on the adjacent periosteal
surface. These results suggest that the canine
prostate cancer cells act in a similar fashion to
human prostate cancer cells.
Clinical significance of bone metastasis
The presence of bone metastases is often asso-
ciated with poor survival time. The patient’s sur-
vival is dependent on the degree of osseous
involvement. In addition to adversely affecting
survival time, bone metastases cause considerable
morbidity. Bone metastases affect the patient
through several mechanisms. They can induce
pain due to microfracture and gross fracture.
If the extent of metastatic volume is severe,
myelophthisis may occur. Bone pain is poorly
localized and often described as a deep ache
accompanied by occasional sharp discomfort. The
pain is not related to any event, but eventually
becomes more prominent and may be aggravated
Table 1. Tumours metastatic to bone in dogs (a review of the literature)
Primary tumour Reference
Chemodectoma (Szczech et al., 1973)
Cutaneous squamous cell carcinoma (Jonsson & Gustafsson, 1973)
Sebaceous gland carcinoma (Case et al., 1969)
Mammary carcinoma (Misdorp & den Herder, 1966)
Pheochromocytoma (Stowater, 1979; Barthez et al., 1997)
Aortic body tumour (Montgomery et al., 1980)
Urinary bladder carcinoma (Cooley & Waters, 1998)
Prostate carcinoma (Durham & Dietze, 1986; Lee-Parritz & Lamb, 1988; Cornell et al., 2000)
Transmissible venereal tumour (Padovan et al., 1987)
Malignant mesothelioma (Smith & Hill, 1989)
Renal cell carcinoma (Arai et al., 1991)
Uveal melanoma (Rovesti et al., 2001)
Nephroblastoma (Terrell et al., 2000)
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by movement. The origin of the bone pain is not
proven; however, it may arise from stimulation of
pain receptors in either the periosteum or endo-
steum. Mechanical stimulation can result from the
growing tumour mass, formation of microfractures
or development of pathologic fractures.
Treatment for bone metastasis is mainly pallia-
tive and is aimed at reducing pain and further
bone destruction and improving quality of life.
Owing to increased osteolytic activation of certain
bone metastatic tumours, dogs may show signs of
pain, hypercalcaemia, neurological signs with
spinal metastasis and pathological fractures. In
humans, bisphosphonates, which inhibit osteo-
clast-induced bone resorption, are commonly
used to interfere with tumour-induced bone
osteolysis (Green, 2002). These agents have been
documented to reduce bone pain; however, there
is no clear correlation between administration of
bisphosphonate and tumour response. Other
options include radioisotopes used either alone
or with external beam radiotherapy to reduce the
pain induced by skeletal metastases (Siegel & Cronin,
1997; Ramirez et al., 1999; Serafini, 2001). These
treatments, combined with surgery to improve
bone stability, and analgesia can provide effective
palliation of symptoms for the majority of patients
(Gilson, 1998; Lester & Gaynor, 2000).
Recent advances in understanding the biology
of osteoclasts has led to the development of novel
compounds to inhibit bone resorption. Of parti-
cular note is the identification of a key osteoclas-
togenic factor, receptor activator of NFkB ligand
(RANKL). In normal bone, osteoblastic cells regu-
late osteoclastogenesis and osteoclast activity by
interacting with mononuclear haematopoietic
osteoclast precursors (Roodman, 1996). The
molecular mediator of this interaction was shown
to be the osteoblast-expressed protein RANKL.
Binding of RANKL to RANK on the osteoclast
precursor initiates a cascade of intracellular signals
that culminate in the acquisition and activation
of the osteoclast phenotype (Lacey et al., 1998;
Yasuda et al., 1998). The osteoblast also produces
osteoprotegerin (OPG) that regulates excessive
bone resorption by acting as a soluble decoy
receptor for RANKL (Simonet et al., 1997). Thus,
OPG neutralizes the RANKL–RANK interaction,
resulting in the inhibition of osteoclastogenesis.
OPG is currently in human clinical trials to test
its efficacy in bone metastasis.
Mediators of osteoblastic metastasis
A variety of factors may contribute to cancer-
mediated bone mineralization. Prostate cancer
cells produce a variety of factors that have direct
or indirect osteogenic properties (Table 2)
(Yoneda, 1998; Boyce et al., 1999; Deftos, 2000).
Some of these factors, such as bone morphoge-
netic proteins (BMPs) (Harris et al., 1994; Autzen
et al., 1998; Hullinger et al., 2000) and endothelin-1
(ET-1) (Nelson et al., 1995), may directly stimu-
late differentiation of osteoblast precursors to
mature mineral-producing osteoblasts. Other fac-
tors such as parathyroid hormone-related protein
(PTHrP) may work through inhibition of osteo-
blast apoptosis (Karaplis & Vautour, 1997;
Cornish et al., 1999). Additionally, there are pro-
teins that may work indirectly to enhance bone
production, such as the serine proteases, prostate-
specific antigen and urinary plasminogen activa-
tor, which can activate latent forms of osteogenic
Table 2. Osteoblastic factors produced by tumour cells
Factor Reference
Bone morphogenetic proteins (Bentley et al., 1992; Hullinger et al., 2000)
Endothelin-1 (Nelson et al., 1995; Nelson & Carducci, 2000)
Insulin-like growth factors (Perkel et al., 1990; Pirtskhalaishvili & Nelson, 2000)
Interleukin-1 and interleukin-6 (Taguchi et al., 1998; Le Brun et al., 1999)
Osteoprotegerin (Guise, 2000; Honore et al., 2000)
Parathyroid hormone-related peptide (Karaplis & Vautour, 1997; Cornish et al., 1999)
Transforming growth factor-b (Killian et al., 1993)
Urinary plasminogen activator (urokinase) (Goltzman et al., 2000)
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proteins, such as transforming growth factor-b
(Killian et al., 1993; Rabbani et al., 1997). Finally,
some molecules, such as OPG (Simonet et al.,
1997; Guise, 2000; Honore et al., 2000) and ET-1
(in a dual role with its osteoblast-stimulating
activity) (Chiao et al., 2000), can enhance
osteosclerosis through inhibiting osteoclastogen-
esis. Despite this gamut of putative mediators of
prostate cancer-induced osteosclerosis, the
investigators are unaware of in vivo studies that
unequivocally demonstrate their role in this
process. Other tumour types, such as osteosar-
coma, also produce a variety of osteoblastic factors
(Wlodarski & Reddi, 1987; Raval et al., 1996;
Laitinen et al., 1998). It is most likely that several
of these osteogenic factors work in concert to
produce maximal bone production.
In one study, normal dog prostate tissue was
implanted subcutaneously over mouse calvaria
(LeRoy et al., 2002). The prostate tissue remained
viable and induced abundant new woven bone
formation on the adjacent periosteal calvarial sur-
face, and in some cases, new bone formation was
also induced on the concave calvarial periosteum.
These results are consistent with the pro-
osteoblastic activity of prostate cancer and suggest
that non-transformed prostate cells themselves
are pro-osteoblastic. Intriguingly, osteoclast activ-
ity within the bone was also increased, suggesting
that the overall bone remodelling is increased by
the prostate cells.
Mediators of osteoclastic metastasis
A number of reports have shown that osteoclastic
bone resorptive lesions are important to the devel-
opment of bone metastases in several cancer types,
including breast cancer, lung cancer and prostate
cancer (Yoneda, 1998). These cancers may induce
osteoclast activity through secretion of interleukin-1a,
PTHrP or prostaglandin-E2 (PGE2) (Guise et al.,
1996; Mundy, 1997; Akatsu et al., 1998).
Tumour-mediated osteolysis in some instances,
such as breast cancer, however, occurs indirectly
through expression of molecules, such as PTHrP,
that induce RANKL in osteoblasts (Roodman,
1999; Thomas et al., 1999). This contrasts with
the observations that giant-cell tumours directly
promote osteoclast activity via RANKL (Atkins
et al., 2001) and that prostate cancer cells
directly induce osteoclastogenesis through
RANKL (Zhang et al., 2001a). Another factor
that may play a role in tumour-induced osteo-
clastogenesis is human macrophage inflamma-
tory protein-1a, which has been shown to be
produced by myeloma cells (Han et al., 2001).
Because of the osteoclastic activity induced by
many neoplasms, antiresorptive agents such as
bisphosphonates or anti-PTHrP neutralizing
antibody have been reported in breast cancer
animal models to block tumour expansion in
bone (Sasaki et al., 1995; Alsina et al., 1996).
Furthermore, OPG has been shown to inhibit
primary bone sarcoma-induced osteolysis and
tumour-induced bone pain but not tumour bur-
den in mice (Honore et al., 2000). OPG, however,
not only blocked osteolytic bone metastasis
induced by human neuroblastoma NB-19 cells
(Michigami et al., 2001) but also reduced tumour
burden in that model.
In vivo methods for research on bone
metastasis
Advances in exploring the biology of prostate
cancer skeletal metastasis have been hampered by
the lack of good animal models. The ideal model
to examine prostate cancer skeletal metastasis
should include all aspects of the metastatic
cascade, from primary tumour formation through
overt metastases. Additionally, production of
bone lesions that contain both osteoblastic
and osteolytic components and, preferably,
allowing for modelling the interaction between
human tumour cells and human bone should
be utilized in comparative models. An excellent
review of human prostate cancer skeletal meta-
stasis models has been recently published (Zhau
et al., 2000). We describe several novel models
below.
One model recently developed for the compara-
tive study of human prostate cancer is the severe
combined immunodeficient (SCID) human
system (Nemeth et al., 1999). In this model
(Fig. 1), macroscopic (1 cm) fragments of human
fetal bones (femora and humeri) were implanted
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subcutaneously into SCID mice. After implant-
ation, the bone fragments remained anatomically
intact with recognizable cortical and trabecular
bone and bone marrow. After several weeks,
human prostate cancer cells (from established
prostate cancer cell lines or prostate cancer
tumour xenografts) were injected into the mice,
either via the tail vein or directly into the marrow
compartment of the implanted bone. Large pros-
tate cancer bone tumours (0.5–1.0 g) developed
over the next 6–12 weeks in the implanted bone
fragment. The tumours were composed of prostate
cancer cells, bone cells and bone stroma/extra-
cellular matrix. Histological examination demon-
strated close interposition of all of these elements
with each other, resulting in a complex tumour
similar in histological appearance to clinical
specimens of bone metastases. Depending on the
cell line used, tumours were predominantly osteo-
lytic, mixed osteolytic/osteoblastic or predominantly
osteoblastic, as determined by radiographic and
histological analysis. An advantage of this model
is that human tumour cells are grown in human
bone, as opposed to murine bone. A weakness
of this model, however, is the use of fetal bone,
which has a different composition than adult
bone. To circumvent this weakness, human adult
bone was implanted in mice to study the effects
of osteoclast inhibitors on tumour growth in
bone (Yonou et al., 2003).
To provide an additional assessment of the
metastatic cascade from the vascular system on
through the target site, intracardiac injection of
cancer cells can be performed (Yin et al., 1999).
Mice were re-anaesthetized and tumours were
injected percutaneously into the left ventricle.
After intracardiac injection, tumours typically
developed in the long bones within a period of
4–8 weeks, depending on the cell line used. This
model typically results in a take rate of 80–90%.
The strength of this model is that it requires the
cancer cells to extravasate from the blood vessel to
the metastatic target site, which allows for good
modelling of the later half of the metastatic cas-
cade. A disadvantage is that the spontaneous
release of metastatic cells from a primary tumour
is not evaluated in this model.
One challenge with animal models is identifying
locations of metastases at multiple sites and moni-
toring tumour growth in bone. Typically, measure-
ments are made using radiographs. Radiographs,
however, have several drawbacks, including:
(1) lack of sensitivity, as over 50% of the bone
mineral density has to change prior to it being
detected as a change on radiographs; (2) they









Figure 1. Schematic of the severe combined immunodeficient (SCID)-Hu model. Fetal long bone was longitudinally
sectioned in half and implanted subcutaneously into the SCID mouse. The cross section demonstrates the implant location,
with the open marrow section being placed adjacent to muscle and subcutaneous tissue and skin overlying the implant.
Four weeks after implantation of bone, tumour cells were injected either directly into the marrow cavity or intravascularly.
Biology of skeletal metastases 135
ª 2003 Blackwell Publishing Ltd, Veterinary and Comparative Oncology, 1, 3, 131–139
bone and do not allow quantitative determination
of total tumour volume; and (3) they are an indirect
measure of the tumour, as they only identify the
effect of tumour on bone, not the tumour itself.
Recent advances in fluorescent (Hoffman, 2001)
and luminescent imaging (Zhang et al., 2001b)
have provided sophisticated and sensitive methods
to identify and quantify tumour growth in vivo
(Huang et al., 2002). Briefly, cancer cells were
engineered to express fluorescent or luminescent
markers and then injected into mice through a
variety of routes. This methodology can be used
to identify tumour growth in bone (Fig. 2), thus
providing a great opportunity to explore the
biology of bone metastasis.
Conclusion
Bone metastases are a frequent and debilitating
aspect of cancer. Advances in bone biology are
leading to a better understanding of the patho-
physiology of bone metastases. Furthermore,
novel laboratory animal models and tumour-
imaging technologies should facilitate defining the
mechanisms of bone metastasis.
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Figure 2. Luminescent imaging of prostate tumour in bone. A human prostate cancer cell line was engineered to express a
luminescent signal (luciferase). The cancer cells were then injected into the tibia of mice and allowed to grow. After several
weeks, the mice were subjected to imaging. The upper mouse was not injected with tumour cells. The lower mouse’s right
tibia was injected with tumour cells. Luciferase activity is indicated by the colours in the tibia. The scale indicates the degree
of luminescent activity.
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